Matinas BioPharma Holdings (MTNB) Non-Current Deferred Tax Liability (2015 - 2026)

Matinas BioPharma Holdings (MTNB) has 12 years of Non-Current Deferred Tax Liability data on file, last reported at $257000.0 in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $257000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $257000.0 (changed 0.0% YoY), and the FY2025 annual result was $257000.0, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability steadied at $257000.0 in Q1 2026 per MTNB's latest filing, from $257000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $341265.0 in Q1 2022 and troughed at $257000.0 in Q4 2024.
• A 5-year average of $311399.7 and a median of $341000.0 in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deferred Tax Liability changed 0.0% in 2022, then fell 24.63% in 2024.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $341000.0 in 2022, then changed by 0.0% to $341000.0 in 2023, then slipped by 24.63% to $257000.0 in 2024, then changed by 0.0% to $257000.0 in 2025, then changed by 0.0% to $257000.0 in 2026.
• Business Quant data shows MTNB's Non-Current Deferred Tax Liability at $257000.0 in Q1 2026, $257000.0 in Q4 2025, and $257000.0 in Q3 2025.